p53介导间质性膀胱炎抗增殖因子（APF）诱导的人膀胱上皮细胞生长抑制。
p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells.
作者信息
Kim Jayoung, Keay Susan K, Dimitrakov Jordan D, Freeman Michael R
机构信息
The Urological Diseases Research Center, Children's Hospital Boston, Boston, MA 02115, USA.
出版信息
FEBS Lett. 2007 Aug 7;581(20):3795-9. doi: 10.1016/j.febslet.2007.06.058. Epub 2007 Jul 2.
Abstract
Antiproliferative factor (APF) is a sialoglycopeptide elevated in the urine of patients with interstitial cystitis, a urinary bladder disorder of unknown etiology that is characterized by chronic pelvic pain. The present study was directed toward uncovering a pathway through which APF signals. Treatment of human urothelial cells with native APF resulted in growth inhibition accompanied by blockade of cell cycle transit and increased p53. Reduced expression of p53 by RNA interference diminished, while ectopic expression of p53 mimicked, the effects of APF. These are the first findings implicating the network of p53 target genes in urothelial defects associated with interstitial cystitis.
摘要
抗增殖因子（APF）是一种唾液酸糖肽，在间质性膀胱炎患者的尿液中含量升高。间质性膀胱炎是一种病因不明的膀胱疾病，其特征为慢性盆腔疼痛。本研究旨在揭示APF发出信号的途径。用天然APF处理人膀胱上皮细胞会导致生长抑制，同时伴有细胞周期进程受阻和p53增加。通过RNA干扰降低p53的表达可减弱APF的作用，而p53的异位表达则模拟了APF的作用。这些是首次表明p53靶基因网络与间质性膀胱炎相关的膀胱上皮缺陷有关的发现。
相似文献
1
p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells.
FEBS Lett. 2007 Aug 7;581(20):3795-9. doi: 10.1016/j.febslet.2007.06.058. Epub 2007 Jul 2.
2
A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2.
PLoS One. 2012;7(12):e50392. doi: 10.1371/journal.pone.0050392. Epub 2012 Dec 6.
3
Quantitative proteomics identifies a beta-catenin network as an element of the signaling response to Frizzled-8 protein-related antiproliferative factor.
Mol Cell Proteomics. 2011 Jun;10(6):M110.007492. doi: 10.1074/mcp.M110.007492. Epub 2011 Mar 21.
4
Antiproliferative factor regulates connective tissue growth factor (CTGF/CCN2) expression in T24 bladder carcinoma cells.
Mol Biol Cell. 2012 May;23(10):1976-85. doi: 10.1091/mbc.E11-08-0714. Epub 2012 Mar 21.
5
Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells.
J Exp Clin Cancer Res. 2010 Dec 10;29(1):160. doi: 10.1186/1756-9966-29-160.
6
Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator.
BMC Urol. 2004 Apr 6;4:3. doi: 10.1186/1471-2490-4-3.
7
Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by d-proline and d-pipecolic acid derivatives of antiproliferative factor.
Chem Biol Drug Des. 2011 Jun;77(6):421-30. doi: 10.1111/j.1747-0285.2011.01108.x. Epub 2011 Apr 27.
8
An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide.
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11803-8. doi: 10.1073/pnas.0404509101. Epub 2004 Jul 28.
9
Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo.
BJU Int. 2012 Dec;110(11 Pt C):E1138-46. doi: 10.1111/j.1464-410X.2012.11299.x. Epub 2012 Jun 28.
10
c-Jun is involved in interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human bladder cancer T24 cells.
Urol Oncol. 2013 Feb;31(2):228-33. doi: 10.1016/j.urolonc.2010.11.011. Epub 2011 Aug 26.
引用本文的文献
1
Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome.
Biomedicines. 2022 Sep 23;10(10):2380. doi: 10.3390/biomedicines10102380.
2
Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.
Diagnostics (Basel). 2021 Dec 29;12(1):75. doi: 10.3390/diagnostics12010075.
3
Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives.
Diagnostics (Basel). 2021 Nov 30;11(12):2238. doi: 10.3390/diagnostics11122238.
4
Cyclin-dependent kinase 1 shows to be a potential genetic target for chemical cystitis.
Immun Inflamm Dis. 2021 Sep;9(3):950-958. doi: 10.1002/iid3.454. Epub 2021 Jun 3.
5
Cytoskeleton-Associated Protein 4, a Promising Biomarker for Tumor Diagnosis and Therapy.
Front Mol Biosci. 2021 Feb 5;7:552056. doi: 10.3389/fmolb.2020.552056. eCollection 2020.
6
Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects.
Int Neurourol J. 2020 Mar;24(1):29-40. doi: 10.5213/inj.1938186.093. Epub 2020 Mar 31.
7
Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome.
Toxins (Basel). 2019 Nov 19;11(11):676. doi: 10.3390/toxins11110676.
8
Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review.
Int Urogynecol J. 2019 Nov;30(11):1785-1794. doi: 10.1007/s00192-019-04075-9. Epub 2019 Aug 13.
9
Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency.
Tzu Chi Med J. 2019 Jul-Sep;31(3):135-143. doi: 10.4103/tcmj.tcmj_92_19.
10
Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A.
Sci Rep. 2018 Mar 14;8(1):4505. doi: 10.1038/s41598-018-22771-2.
本文引用的文献
1
Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review.
J Urol. 2007 Feb;177(2):450-6. doi: 10.1016/j.juro.2006.09.032.
2
Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
Cold Spring Harb Symp Quant Biol. 2005;70:489-97. doi: 10.1101/sqb.2005.70.049.
3
hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Cell. 2005 Dec 16;123(6):1065-78. doi: 10.1016/j.cell.2005.09.032.
4
Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis.
J Urol. 2005 Dec;174(6):2382-7. doi: 10.1097/01.ju.0000180417.11976.99.
5
Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stress.
Cancer Res. 2005 Sep 15;65(18):8242-9. doi: 10.1158/0008-5472.CAN-05-0942.
6
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
EMBO J. 2005 Oct 5;24(19):3411-22. doi: 10.1038/sj.emboj.7600812. Epub 2005 Sep 15.
7
ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
Cell Cycle. 2005 Sep;4(9):1166-70. doi: 10.4161/cc.4.9.1981. Epub 2005 Sep 29.
8
The p53 pathway: positive and negative feedback loops.
Oncogene. 2005 Apr 18;24(17):2899-908. doi: 10.1038/sj.onc.1208615.
9
Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61. doi: 10.1073/pnas.0408595102. Epub 2005 Mar 23.
10
An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide.
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11803-8. doi: 10.1073/pnas.0404509101. Epub 2004 Jul 28.
Zotero 插件